Table 1.
Review of SABR literature for primary RCC
| Author / Year | Patients | Follow-up (months - Median or Mean) | Average marginal dose (Gy) | Outcome - Crude Local control | Estimated 2 year LC | Overall Survival Median | Toxicities |
|---|---|---|---|---|---|---|---|
| Chang et al. [7] 2016 | 16 | 19 | 30-40Gy in 5 fractions | 100% | NR | NR | 1 grade 2 acute toxicity and 2 grade 4 late toxicities |
| Gilson et al. [8] 2006 | 33 | 17 | Median 40Gy in 5 fractions | 94% | 92 | NR | NR |
| Lo et al. [9] 2014 | 3 | 21.7 | 40Gy in 5 fractions | 100% | NR | NR | Early: 1 x Grade 1 nausea Late: nil |
| McBride et al. [10] 2013 (abstract) [prospective] | 15 | 36.7 | Median 33Gy in 3 fractions | 87% 1 failure at 30.7 mo 1 failure at 31.2 mo |
NR | NR | 1 x Grade 3 renal toxicity 5 x Grade 1 fatigue 2 x Grade 1 nausea |
| Nair et al. [27] 2013 | 3 | 13.3 | 39Gy in 3 fractions | 100% | NR | NR | Early: 1 x Grade 1 nausea Late: Nil |
| Nomiya et al. [28] 2008 | 10 | 57.5 | Median 4.5Gy x 16fx | 100% | 100 | 5 year OS 74% | 10% Grade 4 toxicity, no other toxicities > Grade 1 |
| Qian et al. [29] 2003 (abstract) | 20 | 12 | 40Gy in 5 fractions | 93% | 86 | NR | NR |
| Pham et al. [15] 2014 [prospective] | 20 | 6 | 26Gy in 1 fraction 42Gy in 3 fractions | NR | NR | NR | 60% Grade 1–2 No Grade 3, Grade 4 |
| Ponksy et al. [30] 2015 [prospective] | 19 | 13.7 | Max 48Gy in 4 fractions | NR | NR | NR | 5.2% Grade 2, 15.8% Grade 3–4 |
| Siva et al. [16] [prospective] | 33 | 24 | 26Gy in 1 fraction 42Gy in 3 fractions | 97% | 100% | 2 year OS 92% | 78% Grade 1–2 3% Grade 3 |
| Svedman et al. [31] 2006 [prospective] | 5 | 52 | 40Gy in 4 or 5 fractions, 45Gy in 3 fractions | 80% | 91 | Median survival 32 months | 89% Grade 1–2, 4% Grade 3 |
| Svedman et al. [32] 2008 | 7 | 39 | 40Gy in 4 fractions | 86% | 91 | NR | 58% Grade 1–2, nil else |
| Teh et al. [33] 2007 (abstract) | 2 | 9 | 24Gy–48Gy in 3–6 fx | 100% | 100 | NR | NR |
| Staehler et al. [18] 2015 b [prospective] | 30a | 28.1 | 25Gy in 1 fraction | 98% (at 9mo) b |
NR | Not attained after median 28.1 months+ | 13% Grade 1–2 nil else |
| Wang et al. [13] 2014 | 9 | 38.3 | 36-51Gy to 50% isodose line at 3-5Gy per fraction | 5 year LC 43% | NR | 5 year OS 35% | Early: 44% Grade 1 (GI, haem.) Late: 22% Grade 2 (GI) |
| Wersall et al. [34] 2005 | 8 | 37 | 40Gy in 4 or 5 fractions, 45Gy in 3 fractions | 100% | 100 | Median survival 58+ months | 20% Grade 1–2, 19% Grade 3, nil Grade 4+ |
a report included an additional 15 patients with Transitional cell carcinoma;
b pooled results with patients treated for TCC
NR not reported, Gy Gray